BREAST CANCER BASE

The weakness of breast cancer cells Sweden and the United Kingdom two research team found that a new cell is the target for the prevention and possible treatment of certain ke...

1), arbitrary treatment

Many people in the medical seriousness of the lack of understanding, often in the treatment of choice method, application specific therapy to add a lot of random ingredients. In some other disease patients may not have serious adverse consequences, but in the treatment of breast cancer is extremely intolerable. Such arbitrariness is itself on the medical facts of contempt, to the challenges of nature. But do not respect the law will be punished by law, the end of the day or lose their patients. We already know that the application of conventional means of treatment, thousands of human knowledge is the crystallization. In the beginning of their birth had been random, is not perfect, or even invalid. After a lot of serious study and practice, and after repeated eliminated with the changes, these therapies have gradually matured, and the mix of various therapies are becoming more rational, in accordance with the scientific facts application of these norms therapy is the best chance of survival and best quality of life important safeguards. Arbitrarily change these methods, we could not have guaranteed the same effect, but not without the possibility of lowering effect. Therefore, no clear evidence can lower long-term survival and quality of life issues should not risk being tested, including those other areas boast a very reasonable things and in other cancers do something of value. If the intention is to explore new methods, and should not be arbitrarily, but should be handled by professionals through formal channels after formal approval, so that patients can guarantee the basic interests, but also to maximize the value of information assurance. In short, we should do everything possible to uphold the standard of diagnosis and treatment, there has been a substantial medical facts today with speculation measures enacted treatment is blind risky move. Also, if conveniently be at the expense of issuing the standard treatment, as well as an early stop for good.

2), the first time engaged in casual

Cancer and many other diseases are different, if the initial treatment of unreasonable, even after suffering are more difficult to cover completely. More importantly, the initial misconduct will increase the chance of a relapse, and recurrence of breast cancer after treatment up is extremely difficult. Therefore, do not put a lot of hope are at the mercy of those remedial measures, we should cherish the very initial diagnosis and treatment, to spare no effort to secure the early administration got the best chance of survival and the highest quality of life.

3), priority stereotyped surgery

But surgery to be in the treatment of breast cancer is a historical process. In fact, a few decades ago people began to doubt whether the operation as previously thought in the decisive position. Currently people have breast cancer as a systemic disease, invasive breast cancer, once there stage systemic shift the possibility that the major breast cancer is not fatal harm local violations, but systemic metastasis. Systemic diseases to systemic administration, a large number of medical facts have to turn people into a comprehensive treatment of an era.虽然手术在乳腺癌的治疗中确有其不可替代的作用，并且在少数情况下是唯一的治疗手段，但在绝大多数情况下，不论是从生存机会的角度还是从生活质量的角度，合理有序的综合治疗都是最有优势的。 Therefore, we should not think "Anyway, back to surgery or do", as in anyway to eat or cooked as well. When the surgery, how surgery, in accordance with the specific conditions decision.

4), blindly pursue major surgery

You might think that the greater the surgery on the more clean cut, the easier it is for survival, is only their losses and suffering are large and some others. In fact, this is a very grave miscalculation. But these misconceptions was in the medical profession did have, it has made a bigger and bigger surgical mistakes. The blind expansion of the scope of operation no better efficacy, people will begin to doubt whether this idea has committed a wrong direction, people have begun to explore how to use smaller combat operations in exchange for the same chances of survival. In fact, expanding the scope of operation will not increase the chances of survival of the reasons we are stressing the upside systemic disease concept that many patients before surgery has been the existence of systemic subclinical metastases, or small metastases. These lesions can continue after the development and ultimately life-threatening. Partial resection regardless of how to expand the scope of it or doing anything about these distant metastases.今天我们应用保留乳房等低创伤的手术方法治疗I、Ⅱ乳腺癌，是经过大量设计极为严密和经过长期随访的随机对照研究证实的，其中还包括大量多中心、甚至多国联合进行的前瞻性随机临床对比。 Only participate in such informal study on the number of patients reached about 15,000 people. These methods have been judged to modern medicine most fully studied methods of treatment. Western countries, Japan, Hong Kong and other places, I, II breast cancer using breast-conserving therapy in general the ratio has reached 30% to 60%, or higher, and it is still rising. Unfortunately, domestic treatment too little. We can see that the right of patients suitable for breast-conserving therapy is basically from the nature of breast cancer's decision, which is not merely a human pursuits, and that it is the patients had breast cancer after the misfortune of a lucky coincidence, as one day it would be a coincidence. It can be said that the breast-conserving therapy is aimed at improving neither the expense nor the same chance of survival under the premise that patients live more lighthearted and more near normal. In other words, if you are suitable for breast treatment, the choice of radical surgery surgery not only have to process the crime was more treatment after a lot of mental anguish, and will seriously affect the patient's family and social adaptability. And you have to rely on expectations of radical surgery to get more chances of survival fantasy is actually non-existent. These patients radical surgery is not stopped, which is not only lose out to take advantage of the problem. .

5), chemotherapy blindly small

Since systemic breast cancer metastasis is the most lethal, systemic chemotherapy such measures on the treatment of breast cancer treatment has become a matter of course the core content, except for a few very low risk of relapse patients and the poor minority health can not tolerate chemotherapy patients, is not sufficient reason to systemic therapy can be discounted . Postoperative adjuvant chemotherapy of breast cancer value of the study is very compelling, in addition to a large number of specific studies, the United States early breast cancer trial in collaboration Group (EBCTCG) 1988,1992,1998 respectively, in a meta-analysis was sufficient follow-up time of all prospective randomized study. Among them, in 1998 on the meta-analysis involving 69 specific studies, nearly 30,000 cases, but rather part of the study were followed for at least 15 years. Meta-analysis of these results for breast cancer treatment options is the biggest impact. These studies clearly show that chemotherapy can average risk of breast cancer recurrence reduced l / 4, to reduce the risk of death l / 7. Generally speaking the younger patients, the greater the benefit of chemotherapy, 70 patients over the age of chemotherapy little value. The value of chemotherapy dose intensity have a great relationship now that sufficient quantities of chemotherapy is an important guarantee of survival, strength dose chemotherapy, a patient's chance of survival is not improved, or may even be declining. For example, if someone proves that the application of the most commonly used cyclophosphamide MTX fluorouracil the CMF adjuvant chemotherapy program in dose intensity achieved standards of 85% or more, pre-menopausal patients in the six-year recurrence-free survival rate of 70.6% can be achieved. Because CMF chemotherapy can be reduced by an average of about 1 / 4 of the risk of recurrence, then not be able to estimate the chemotherapy patients in the six-year recurrence-free survival rate should be 63.3%. But the study found that dose intensity to the standards below 65%, of these patients RFS actually only 45.9%. Chemotherapy not enough variety of reasons, but many patients are worried that chemotherapy would reduce the body's immunity and cancer chemotherapy refused norms, they might feel after chemotherapy patients die more quickly. However, we should be based on the facts, especially as survival indicators to judge standards, not on the basis of speculation. Since the facts prove that chemotherapy can people get more chances of survival, then worry about any chemotherapy can reduce the survival rate can speculate whether it. In addition, the dose of chemotherapy drugs is generally based on the patient's body surface area calculation, ordinary Chinese people about the dosage of Europe and the United States is about 80%. Facts prove that the Chinese people's tolerance of chemotherapy is no problem, so not only conventional chemotherapy, foreigners withstand the high-dose chemotherapy Chinese can be used for. So far, different postoperative chemotherapy program's long-term comparison, those which enhance the survival rate of larger programs, and drug side effects are often heavier. Certainly not by the toxic side effects of the re-efficacy is good. Therefore, after chemotherapy in breast cancer, but also can only use certain toxic side effects of the recent price in exchange for the more chances of survival. But in fact the EBCTCG 1998 meta-analysis found that breast cancer patients undergoing chemotherapy for reasons other than not led to the death than do patients in chemotherapy, chemotherapy note on the whole is still quite safe.

6), neglected endocrine therapy

The incidence of breast cancer and estrogen with the stimulant effect. Against estrogen stimulation for the treatment of endocrine therapy is. As many other tumors are not endocrine therapy and endocrine therapy side effects are very minor, a lot of people are not paying enough attention it, but in fact the value of endocrine therapy is unparalleled. Tamoxifen endocrine therapy in breast cancer is the most commonly used drug in history due to insufficient understanding of the drug in the early stages of taking tamoxifen had time is shorter, and the follow-up after treatment was partial short time, thus making it not only the efficacy of tamoxifen has not been fully tapped. Have not been sufficiently substantiated. The United States early breast cancer trial in collaboration Group (EBCTCG) 1988,1992,1998 years of tamoxifen treatment of the prospective randomized study conducted meta-analysis of the study is a large and authoritative. Research indicates that along with the development of the times, postoperative tamoxifen in the average time gradually extended, while tamoxifen on recurrence and mortality rates are also lower rate increase, but with chemotherapy indirect comparison indicates that the use of tamoxifen as an extension of time. It's therapeutic value from chemotherapy than gradually increased to more than chemotherapy. The 1998 analysis, the patients were followed for many has reached 15, while taking l, 2,5 years of tamoxifen are extremely rich. This meta-analysis concluded that the use of tamoxifen as extended time, the risk of recurrence and death decrease in the risk will gradually increase, the change in women under 50 years of age is particularly notable in medication five years on the premise that the effect of the younger patients than older patients not worse. All age groups will be combined together, taking five years of tamoxifen reduced the overall average could be 47% of the risk of recurrence by 26% and the risk of death, and chemotherapy can only overall average 24% lower risk of recurrence and a 15% risk of death. Previously that the young pre-menopausal patients treatment with tamoxifen bad, but may be more time before medication is only 1 ~ 2 years for this. May surprisingly, taking five years of tamoxifen is precisely in the following 40-year-old young women the most notable effect can be reduced 54% of the risk of recurrence and 52% risk of death. While the 50-year-old chemotherapy following tumor estrogen receptor-negative women were the most significant effect can be reduced by 40% the risk of recurrence and 35% risk of death. In addition, tamoxifen in breast cancer prevention are very valuable, taking five years of tamoxifen can happen contralateral to reduce the risk of breast cancer by about half. Had the side contralateral breast cancer after breast cancer in the opportunities will significantly increase use of breast cancer after five years of tamoxifen can also make the risk of contralateral breast cancer dropped about 50%. Moreover, the systemic breast cancer recurrence or metastasis of endocrine therapy patients also valuable, it was even proposed systemic metastasis of breast cancer after endocrine therapy should be given priority treatment. Therefore, the endocrine tamoxifen therapy in the prevention and treatment of breast cancer are truly the main force, we must not forget or neglect the top of anticancer forces.

7), the side effects of tamoxifen exaggerated

Because tamoxifen is used in general surgery, chemotherapy, radiotherapy and other measures, many patients because these treatment methods and the impact of menopause, plus many patients are also close to the age of menopause, menopause syndrome resulting in a series of other ailments and the symptoms are many. It is unfortunate they are often not 'all boil to the top of the tamoxifen. Overseas studies have shown that in breast cancer prevention trials, whether oral tamoxifen women, or oral placebo because women have "side effects" and the withdrawal. We know that the placebo contain any pharmaceutical ingredients, the "side effects" Obviously with the drug itself irrelevant. Therefore, I hope you understand that when tamoxifen oral discomfort is a significant part of the outside tamoxifen causes. 'More common is even more absurd is that people often exaggerate unprovoked tamoxifen increased endometrial cancer risk. In fact, the pros and cons of treatment means that it not only depends on the availability of, but also one of his degree and characteristics. We must be clear, the most fundamental one is a postoperative tamoxifen can halve the risk of relapse and 1 / 4 of the risk of death, the risk of death here refers to the total risk of death, including any factors leading to the deaths, including the deaths due to breast cancer, including endometrial cancer deaths . In other words even if tamoxifen can induce endometrial cancer this calculation, taking five years of tamoxifen is still avoidable l / 4 of death. We can from the 1998 meta-analysis to see the overall pros and cons of tamoxifen treatment of the origins of that tamoxifen can reduce nearly half of the chance of a relapse, and thus avoid a recurrence of many breast cancer as a direct cause of death, the value of any cancer treatment are enormous. In addition, it also can make 10 years of contralateral breast cancer incidence has dropped by 9 / 1000, and tamoxifen increased endometrial cancer each number only 10 4 / 1000.显然这一数值不仅与乳腺癌复发危险的降低幅度远远不在同一个数量级上，也比三苯氧胺降低对侧乳腺癌发生率的幅度要低一半以上。 My endometrial cancer incidence rates than the foundation of Western countries is much lower, taking tamoxifen after endometrial cancer occurred in absolute numbers may also significantly lower than the Western countries. With some domestic breast cancer experts communicate the results, to date there are no tamoxifen cause endometrial cancer precise, it should be said that the Chinese women use tamoxifen will be more secure. Another endometrial cancer is relatively easy treatment, and recurrence of breast cancer is extremely difficult to achieve good long-term results. Therefore, the volume and nature of these two aspects of analysis can be seen as fear of endometrial cancer and refused tamoxifen, this approach will not increase the hope that it will increase the danger of death. In there was no other alternative to drug tamoxifen under the current situation, refused tamoxifen is obviously otherwise unproductive.

8), the only treatment is reviewed

Breast cancer treatment is not well, and almost every breast cancer patients have a certain degree of the risk of recurrence, but after the side had breast cancer in the contralateral breast cancer than the general people. Early detection of these lesions for extended survival period and guarantee the quality of life have a certain sense, but it is also the size of a distinction. For example, if the contralateral breast cancer early detection, particularly in touch has not found a stage, and given reasonable treatment, often life is not to bring additional threat, and therefore early detection of contralateral breast cancer follow-up inspection is the most valuable work. The chest wall and other places purely local recurrence, if reasonable Early treatment often can obtain good results. After breast-conserving therapy of the affected breast local recurrence often can be reviewed in early detection, after radical surgical treatment can often very good chance of survival. Metastatic Breast Cancer, in the beginning of the lymph nodes, soft tissue and bone metastases often slow progress on the lighter side effects of endocrine therapy relatively sensitive, early detection of these metastases are very helpful to extend the survival time of patients and improve the quality of life. Follow-up and review the information or the Hospital sum up experiences, enhance clinical reference to the strong level, but the real value of clinical research absolutely inseparable from the long-term survival outcome of the evaluation, and information on the long-term survival only through long-term follow-up review can be obtained. Therefore, the follow-up review is a fellow of the acts, there were a standardized system for measuring the level of the hospital and the credibility of the information.

9), neglect Asian clinical problems

Breast cancer screening, screening and follow-up, can be found not just satisfied with the touch of clinical disease, but should strive for the very small lesions, it was not touched on the sub-clinical stage it was found. Regardless of the original breast cancer, or metastasis or recurrence of lesions, early detection means that more proactive, and some chance of survival, a better quality of life assurance. But the x-ray and ultrasound examinations means that most of the time can be found subclinical lesions. The technology is already highly developed today, in Europe and the United States a substantial proportion of breast cancer lesions are not touched, Armed still "fluid mass no cancer" stereotypes just as unarmed participants in modern warfare, and the results, after all, is sad. Stay in on the concept When we stick like spears and machetes refused to firearms, will be a serious impediment to my breast cancer treatment and the improvement in the overall, but it will certainly affect a patient's chance of survival and quality of life.

10), the abuse of health products

A pair of the United States, Japan, Taiwan and mainland China four areas antitumor drugs market analysis of statistics, the Chinese mainland endocrine therapy drug market antitumor drugs only 4% of the total, while the other three areas is as high as 20% to 55%; Immunization and support in drug treatment antineoplastic agents on the mainland market as high as 57%, while the other three areas were only 25% to 32%. This shows China's mainland people's minds endocrine therapy and supportive drugs and the status of these three areas is how different. Clinical work often see that the post-operative patients to prescribe medications more often in the tens of dollars took tamoxifen after going to bring hundreds of supplementary drugs.三苯氧胺的强大抗癌功效我们在上文中已经介绍过了，那么辅助药物可以改善乳腺癌病人的生存机会或改善其生活质量吗?或者它们肯定不会妨碍三苯氧胺的抗癌作用吗?有些可能是有答案的，例如粒细胞集落刺激因子prevention and treatment of low leukocyte so that chemotherapy can be carried out as scheduled and make treatment more secure. But many other drugs, especially health goods therapeutic value is not necessarily so sure that they are not even conducted some research, although many of these studies is not difficult conducted. The "Journal of Clinical Oncology," is a world-renowned authority in professional journals, 1998, the last one on a shark cartilage preparation for cancer research reports. Patients are patients with advanced cancer, the normal standard treatment as usual to protect their basic treatment, on the basis of general patients were randomly divided into test and control groups, respectively oral cartilage and placebo medication after two statistical survival and quality of life of their differences. Results showed that oral shark cartilage preparation of these patients to improve their chances of survival and quality of life is not valuable. We do not know around us why there are so many health products, so far I have not conducted such a study, and has in the absence of such information under the premise can be applied to identify what what carcinoma. Frankly speaking, no similar studies have only their therapeutic value can not be sure, but they are not sure whether harmful to the patients, including the possibility of lower chance of survival. In addition, these things other aspects of the adverse effects may not, we did find that some of the so-called can counter the side effects of chemotherapy drugs and health products itself is a very strong side effects, or even more terrible than chemotherapy. The difference is the toxic side effects of chemotherapy at the same time also can improve chances of survival, health products, which may not precise therapeutic value, and perhaps chemotherapy will confront some benefits. We must remember those who are not fully proven to survival and quality of life indicators adversely affect the availability of health products, it is difficult to play the role of health. While taking these things happen not because of fear of endometrial cancer as tamoxifen and out of the clear increased risk of death, but it is also a risky move.